A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Rocapuldencel-T (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 07 Mar 2018 The recruitment status of this study is unknown because trial information has not been verified since 25 March 2016.
- 10 Jun 2017 Biomarkers information updated
- 24 Mar 2016 Planned End Date changed from 1 Feb 2018 to 1 Mar 2018, according to ClinicalTrials.gov record.